Company: JUNS
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010990
Chunk: 50

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 50
---
”
and similar expressions, as they relate to us or the Company’s management, identify forward-looking statements. Such forward-looking
statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s
management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors
detailed in our filings with the SEC.

The following discussion
and analysis of our financial condition and results of operations should be read in conjunction with the financial statements and the
notes thereto contained elsewhere in this Quarterly Report on Form 10-Q. Certain information contained in the discussion and analysis
set forth below includes forward-looking statements that involve risks and uncertainties. Unless the context otherwise requires, “JNS,”
“we,” “us,” “our,” or the “Company” refers to Jupiter Neurosciences, Inc.

Business Overview

We are a clinical stage research and development
company. We have developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. Our platform product,
JOTROL, an enhanced oral formulation of resveratrol, has many potential indications of use for rare diseases. In the larger disease areas,
we are primarily targeting Parkinson’s Disease and Mild Cognitive Impairment/early Alzheimer’s disease.

In December 2024, we received gross proceeds
of $11 million, before deduction of underwriting discounts and other related expenses, in a registered public offering
(“Public Offering”) of 2,750,000 shares of our common stock, par value $0.0001 per share (“common stock”) at
a price of $4.00 per share. In connection with the Public Offering, the Company’s common stock was registered under Section
12(b) of the Exchange Act and began trading on The Nasdaq Capital Market under the symbol “JUNS.”

Business Overview

The Company’s platform product, JOTROL,
is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol.
This platform has many potential indications of use for rare diseases, which include Mucopolysaccharidoses Type 1, Friedreich’s
ataxia and MELAS. In the larger disease areas, we are primarily targeting Parkinson’s Disease and Mild Cognitive Impairment/early
Alzheimer’s disease.

The present primary target for the Company is
treatment of Parkinson’s Disease (PD). The Company completed preclinical activities in